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Inflammationa b s t r a c t
The international cd T cell conference takes place every 2 years. After being held in Denver (USA) in 2004,
La Jolla (USA) in 2006, Marseille (France) in 2008, Kiel (Germany) in 2010 and Freiburg (Germany) in
2012, the cd T cell community gathered this time in Chicago (USA). This conference was organized by
Zheng Chen from 16 to 18 May 2014 at his home institution, the University of Illinois College of Medicine,
and boasted 180 attendants from all over the world and almost 100 submitted abstracts.
 2014 Elsevier Inc. All rights reserved.1. 1984–1987: the discovery of cd T cells (which then became the TCRc chain) in 1984 [2,3] to the full real-‘‘Whether they are still critical to host defense, or whether they rep-
resent an evolutionary relic, is not clear.’’ – Immunobiology, ed.
Charles A. Janeway and Paul Travers, 1st Edition, 1994
‘‘It is not yet clear whether they are still critical to host defense or
whether they represent an evolutionary relic.’’ – Janeway’s
Immunobiology, ed. Kenneth P. Murphy, 8th Edition, 2011
Following on from the previous meeting in Freiburg 2012 [1],
the Chicago 2014 conference started off with a very special treat,
namely the celebration of the 30th anniversary of the discovery
of cd T cells. The first night saw inspiring overviews given by some
of the pioneers in the field who over a very short period of time
made seminal contributions, from the accidental but groundbreak-
ing cloning of an unexpected third chain of the T cell receptorization by 1987 that cd T cells in fact represent an intriguing and
entirely novel lymphocyte subset [4–6]. These entertaining presen-
tations by Adrian Hayday (London, UK), Yueh-hsiu Chien (Stan-
ford, CA), Ilan Bank (Tel Aviv, Israel) and Willi Born (Denver,
CO) included personal accounts of their research during that time
and featured some of the raw data their original conclusions was
based upon, which provided fascinating insight into top notch
immunological research 30 years ago that is still highly relevant
nowadays.
Despite outstanding research on cd T cells ever since, these
immune cells are still widely ignored and are suspiciously ill-repre-
sented in standard textbooks, as indicated by the quotes above. This
negligence has traditionally been due to technical and conceptual
difficulties in our understanding as to how cd T cells are generated
in the thymus, the type of target structures they recognize, and the
contributions they make to homeostasis, immune surveillance,
inflammation, protective immunity and autoimmunity. The Chicago
2014 conference showcased crucial advances in all these areas, as
summarized in this meeting report (Fig. 1). Here we discuss some
of the oral communications and a selection of poster presentations
Fig. 1. View at downtown Chicago from the plane approaching O’Hare International
Airport, 15th May 2014.
4 M. Bonneville et al. / Cellular Immunology 296 (2015) 3–9at the conference, and apologize in advance that many interesting
contributions could not be reviewed due to space limitations. Pre-
senting authors are highlighted in bold throughout the text.
2. cd T cell development: thymic programming, positive
selection, or peripheral expansion?
Considerable progress is beingmade in our understanding of the
developmental pre-programming of cd T cells, in particular of the
generation of IFN-c+ versus IL-17+ cd T cells in the murine thymus
[7]. Miguel Munõz-Ruiz from José Regueiro’s laboratory (Madrid,
Spain) showed that IFN-c+ cd T cell numbers are significantly
reduced, both in the thymus and in the periphery, in mice with
diminished surface TCRcd expression levels due to haploinsuffi-
ciency in two CD3 chains. The impaired TCR signal transduction
in these mice results in a developmental blockade as indicated by
the specific lack of thymic NK1.1+ CD27+ cd T cells, suggesting that
high constitutive TCRcd expression is critical for the development
of IFN-c producing cd T cells.
TCRcd signaling is known to control a transcriptional network
that induces Id3, which in turn inhibits the E2 transcription factor,
HEBAlt.Michelle Anderson (Toronto, Canada) showed that HEBAlt
overexpression in mice increases IL-17+ cd T cell numbers in the
lung, whereas its loss-of-function impairs the expression of RORct
and Sox13, key factors in the IL-17+ cd T cell program. HEBAlt is
expressed before the TCRcd itself, and thus likely constitutes a
TCR-independent transcriptional regulator of IL-17+ cd T cell
development.
The post-transcriptional regulation of cd T cell differentiation
was addressed by Nina Schmolka from Bruno Silva-Santos’s labo-
ratory (Lisbon, Portugal), who showed that ablation of the microR-
NA network in T cell-specific Dicer knock-out mice significantly
impacts on IL-17+ but not IFN-c+ cd T cell numbers. An expressionanalysis of CD27+ versus CD27 CCR6+ cd T cells [8,9] identified a
set of differentially expressed microRNAs whose individual contri-
butions to the differentiation of IFN-c+ versus IL-17+ cd T cells are
being assessed.
cd T cell numbers in the periphery depend on homeostatic
mechanisms that were addressed by two further oral communica-
tions. Vasileios Bekiaris (Lund, Sweden) reported a major role for
the inhibitory receptor B and T lymphocyte attenuator (BTLA) in
controlling CD27 IL-17+ cd T cells. BTLA-deficient mice accumu-
late CD27 IL-17+ cd T cells and are highly susceptible to dermati-
tis, which can be limited by an agonist BTLA antibody.
Interestingly, BTLA expression is regulated by IL-7 and RORct,
which constitute additional key determinants of IL-17+ cd T cell
homeostasis [10].
Yuan Zhuang (Durham, NC) generated a novel tool for cd T cell
research, a Tcrd-CreER mouse line that allows tamoxifen-inducible
gene targeting specifically in cd T cells. Using this strategy to delete
the TCR signaling adaptor, LAT, the impact on dendritic epidermal
T cells (DETC), the murine cd T cell subset that selectively popu-
lates the skin, was assessed. Their data suggest that LAT-dependent
TCR signaling is required for the wound healing activity of DETC
but not for their homeostasis in the skin. Of note, it was recently
shown that DETC progenitors become hyporesponsive to TCR stim-
ulation upon ‘‘agonist selection’’ in the fetal thymus [11]. Future
research will address the dynamics of TCR ligand expression in
the skin, particularly upon stress or transformation.3. cd T cell recognition of target structures: antigens, ligands or
activators?
Several presentations described new ligands for cd T cells and
provided compelling insights into their recognition. Earlier studies
reported a unique role played by Skint1 in the selection and activa-
tion of murine DETC expressing canonical Vc5/Vd1 TCRs [12,13].
However, the mechanisms underlying the exquisite effects of
Skint1 on this particular cd T cell subset have remained unclear.
While Skint1 has thus far been considered as an essentially intra-
cellular molecule [14], new results presented by Ben Willcox (Bir-
mingham, UK) suggest that key determinants of DETC selection are
actually located on an exposed extracellular loop of Skint1, which
raises the possibility for direct interactions between this molecule
and the Vc5/Vd1 TCR.
In analogy to these observations on Skint1, another member of
the extended B7 receptor family, butyrophilin 3 (BTN3, CD277),
has been reported to play a crucial role in the selection of human
Vc9/Vd2 T cells [15]. However, there are conflicting views
regarding its mode of action. Data from Gennaro de Libero (Basel,
Switzerland) suggested that BTN3 may act as a true presenting
molecule for phosphoantigens such as isopentenyl pyrophosphate
(IPP) and (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate
(HMB-PP) [16]. In contrast, Erin Adams (Chicago, IL) showed that
phosphoantigens instead interact with the intracellular B30.2
domain of BTN3A1, and subsequently switch BTN3 molecules from
a neutral to a stimulatory conformation following inside-out
signaling [17].
The latter model is supported by a new mutagenesis approach
presented by Craig Morita (Iowa City, USA) and biochemical stud-
ies summarized by Andrew Wiemer (Storrs, CT) [18] that argue
against phosphoantigen interaction with the extracellular part of
BTN3, and indicate a primarily intracellular mode of action of
phosphoantigens. If confirmed, these findings would indicate that
phosphoantigens are not bona fide ‘‘antigens’’, i.e. are not displayed
on the cell surface in the context of antigen-presenting molecules.
Further insight was provided by Zsolt Sebestyén from Jürgen
Kuball’s laboratory (Utrecht, The Netherlands) who identified Rho
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antigen-induced Vc9/Vd2 T cell activation. Since Rho GTPases are
known to regulate changes in the actin cytoskeleton, they might
be involved in the postulated inside-out signaling induced upon
interaction between phosphoantigens and the B30.2 domain. Gen-
naro de Libero (Basel, Switzerland) described additional factors,
including a particular ABC transporter, that appear to play an
exquisite role in translocating phosphoantigens from inside to out-
side the cell. It is currently unclear whether these transporters
could contribute to phosphoantigen internalization as well, to
allow rapid activation of Vc9/Vd2 T cells by exogenous IPP or
HMB-PP. Finally, analyses of CHO cell heterokaryons by Thomas
Hermann (Würzburg, Germany) suggest a key role for undefined
primate-specific molecules encoded by genes from chromosome
6 in the BTN3-mediated activation process [19].
These studies leave the issue open as to how interaction
between BTN3 and phosphoantigen ultimately leads to Vc9/Vd2
T cell activation. Does it promote recruitment of yet undefined
Vc9/Vd2 TCR ligands or cognate interactions between Vc9/Vd2
TCR by BTN3? As current studies suggest very low affinity interac-
tions (if any) between the TCR and resting BTN3 molecules, one
might posit the occurrence of conformational changes of the extra-
cellular domain of BTN3, which in turn would enhance the affinity
of Vc9/Vd2 TCR/BTN3 interactions. This hypothesis is appealing
from an evolutionary standpoint since together with the recent
developments in Skint1 biochemistry [14], it would support a con-
served mode of stress sensing shared by murine DETC and human
Vc9/Vd2 T cells.
In line with a constrained molecular context of TCRcd antigen
recognition, recent studies showed the occurrence of CD1d-reac-
tive cd T cells in humans and mice. At this meeting, Derek Doherty
(Dublin, Ireland) identified human Vd3+ T cells that killed target
cells through a mechanism that required CD1d but not the NKT cell
agonist a-galactosylceramide [20]. Adam Uldrich from Dale God-
frey’s laboratory (Melbourne, Australia) and Adrienne Luoma
from Erin Adam’s laboratory (Chicago, IL) described human Vd1+
cd T cell clones displaying CD1d-restricted autoreactivity, and pro-
vided structural insights into how the cd TCR interacts with these
CD1d/glycolipid complexes [21,22]. These studies show an unusual
docking mode of the cd TCR onto CD1d complexes, and are remi-
niscent to the recognition of endothelial protein C receptor (EPCR)
by a human cd T cell clone reported previously [23], since EPCR
shows striking structural similarities with CD1d.
Arguing against a restricted molecular context of TCRcd recog-
nition and lack of clear co-evolution between the TCRcd and a lim-
ited set of related counter-receptors, studies from the teams of
Yueh-hsiu Chien (Stanford, CA), Julie Déchanet-Merville (Bor-
deaux, France), Willi Born (Denver, CO) and others suggest recog-
nition of diverse ligands, including immunoglobulin-related as
well as immunoglobulin-unrelated molecules including phycoery-
thrin, ephrin receptor tyrosine kinase A2, annexin A2, HLA-I free
heavy chain and dimerized insulin [1,24,25]. Such a view would
be consistent with a more general immunoglobulin-like mode of
antigen recognition by the TCRcd, thus allowing triggering of cd
T cell responses in much broader stress-related contexts than ab
T cells. If confirmed, this would make the task of deciphering the
antigen recognition repertoire of cd T cells far more difficult than
initially expected.4. cd T cells and their neighborhood: stimulation, inhibition and
crosstalk
Like many other immune players, cd T cells are essentially soci-
able cells whose performance is strongly influenced by the interac-
tions they establish with their institutional targets (i.e., pathogens,stressed tissues, cancer cells) but also fine-tuned by the microenvi-
ronment in which these interactions occur. Two conference ses-
sions were dedicated to the molecular and cellular mechanisms
involved in the regulation of cd T cell activation, the contribution
of bystander cells, and the possibility of exploiting these interac-
tions for therapeutic purposes.
Hongbo Shen from Zheng Chen’s laboratory (Chicago, IL)
showed that APC contact with Vc9/Vd2 T cells is required for the
ability of IL-23 to induce the proliferation of HMB-PP activated
Vc9/Vd2 T cells [26]. HMB-PP/IL-23-expanded Vc9/Vd2 T cells
from infected macaques had multi-effector function as judged by
their production of IL-17, IL-22, IL-2 and IFN-c, with autocrine pro-
duction of IFN-c enhancing the expansion of recall-like Vc9/Vd2 T
cells.
Mary Poupot (Toulouse, France) reported about their work to
amplify Vc9/Vd2 T cells with highly preserved anti-tumor func-
tions in the absence of IL-2. They focused their attention on IL-33
which amplifies both Th1 and Th2 immune responses, and con-
cluded that IL-33 is worthy of further investigation to replace
exogenous IL-2 for better safety profiles in phosphoantigen-acti-
vated Vc9/Vd2 T cell based clinical trials.
The functional outcome of cd T cell responses is dictated not
only by TCR engagement and co-stimulatory cytokines, but also
fine-tuned by inhibitory and/or activatory co-receptors on their
cell surface [27]. Inhibition or prevention of cd T cell activation
can be beneficial in selected situations such as maintenance of tol-
erance at the maternal–fetal interface. Cristiana Cairo (Baltimore,
MD) showed that most adult Vc9/Vd2 T cells express CD70 after
stimulation whereas CD70 expression by neonatal Vc9/Vd2 T cells
is tightly regulated, thereby possibly contributing to limiting
inflammatory responses.
Inhibition of inflammatory cd T cell responses might be benefi-
cial in cord blood but can be deleterious in cancer patients or other
clinical settings. Daniel Olive (Marseille, France) provided evi-
dence that BTLA on the cell surface of Vc9/Vd2 T cells impairs their
ability to respond to TCR-independent or TCR-dependent stimula-
tion via interaction with herpes virus entry mediator (HVEM)
expressed by lymphoma cells. Interference with the BLTA/HVEM
axis could thus be a possible strategy to recover anti-tumor
immune functions of Vc9/Vd2 T cells in lymphoma patients.
Other reports significantly enriched the co-signaling landscape
by providing new data on regulatory pathways operative in cd T
cells. Janice Telfer and Cynthia Baldwin (Amherst, MA) addressed
the function of WC1 proteins on bovine cd T cells [28]. These pro-
teins are members of the scavenger receptor cysteine-rich (SRCR)
superfamily that have the potential to act as both co-stimulatory
receptors and pattern recognition receptors for ligands expressed
by spirochetes and mycobacteria. In the murine system, expression
of Skint1 by thymic epithelial cells and keratinocytes is essential
for the selective development of DETCs [29]. Anett Jandke from
Adrian Hayday’s laboratory (London, UK) provided evidence sug-
gesting that DETC development and peripheral expansion in the
skin is regulated by both Skint1 and the related molecule Skint2
as epithelial determinants of DETCs at steady state and upon stress.
Besides through the action of inhibitory and costimulatory co-
receptors, homeostasis, activation and functional differentiation
of cd T cells are regulated by the tight interplay with bystander
cells in the local microenvironment. Intraepithelial lymphocytes
(IEL), which include both ab and cd T cells, represent an important
barrier in the prevention of infection against enteric pathogens.
Karen Edelblum (Chicago, IL) reported that cd IEL migration and
interaction with the intestinal epithelium via occludin and
CD103 are essential to the maintenance of mucosal homeostasis
and immediate host response to intestinal pathogens. Other
important IEL regulators are proteins encoded by butyrophilin-like
proteins [30]. Cristina Lebrero-Fernández from Anna Bas Fors-
Fig. 2. Conference organizer Prof. Zheng W. Chen from the University of Illinois
College of Medicine in Chicago during his welcome speech, 16th May 2014.
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form heteromeric protein complexes with Btnl1, and that these
complexes can induce proliferation of IELs in the presence of IL-2
and in the absence of TCR engagement, indicating that Btnl pro-
teins contribute to the functional regulation of T cell mediated
gut immunity.
Keith Thompson (Aberdeen, UK) confirmed the capacity of
Vc9/Vd2 T cells to interact with cells outside the immune system
by showing unexpected interactions between osteoclasts and cd
T cells leading to enhanced activation of cd T cells on one hand
and suppression of osteoclast differentiation and function on the
other hand, suggesting an involvement of Vc9/Vd2 T cells in the
inhibition of bone resorption upon administration of amin-
obisphosphonates [31].
The complexity of interactions between cd T cells and other
immune and non-immune cells in normal, inflamed, or cancer tis-
sues can represent a major constraint to develop strategies to spe-
cifically activate and locally exploit distinct subsets of cd T cells. To
this end, Anna Capsomidis from John Anderson’s laboratory (Lon-
don, UK) reported a comprehensive analysis of the expression of
costimulatory receptor-ligand pairs on Vd1+, Vd2+, and non-Vd1/
non-Vd2 T cells after 28 days of incubation with K562-derived arti-
ficial antigen presenting cells (aAPCs) [32]. Their results show that
this assay allows the expansion of different cd T cell subsets in suf-
ficient amounts for subsequent in vitro and in vivo functional
analyses.
The potential of cd T cells to orchestrate immune responses was
strengthened by Andreea Petrasca from Derek Doherty’s labora-
tory (Dublin, Ireland) who showed that Vc9/Vd2 T cells can induce
maturation of both B cells and dendritic cells (DC) into antigen-
presenting cells (APCs). Interestingly, Vc9/Vd2 T cells prime B cells
to stimulate Th2 responses, whereas they prime DC to stimulate
Th1 responses. Matt Morgan from Matthias Eberl’s laboratory
(Cardiff, UK) showed that Vc9/Vd2 T cells and MAIT cells respond
to human neutrophils after phagocytosis of microbial pathogens,
and in turn mediate the differentiation of bystander neutrophils
into APCs for both CD4+ and CD8+ T cells [33]. Taken together these
findings support the existence of a peripheral immune surveillance
network comprised of unconventional T cells and neighboring
immune and non-immune cells [34], and identify a unique and
decisive role for human cd T cells in shaping the transition of the
innate to the adaptive phase of immune responses.5. cd T cells in infection: regulation, exacerbation, or
protection?
The partaking of cd T cells in the riposte to pathogens is widely
recognized in many different infectious scenarios in mouse models
and in human pathologies. There is undeniable evidence for the
expansion of particular cd T cell subsets in the blood or in infected
tissues. However, dissecting whether these cells have a genuine
anti-infectious function and are involved in protective immunity,
exacerbate the inflammatory response and hence the pathogenic-
ity, or act as general immune regulators is a challenging task, espe-
cially in vivo.
Over the last years, advances in our understanding of the anti-
infectious function of cd T cells have been made by the team of
Zheng Chen (Chicago, IL) (Fig. 2) through studies in a macaque
model of tuberculosis [35]. In this meeting, Arwa Qaqish from this
laboratory exposed the capacity of adoptively transferred autolo-
gous Vc9/Vd2 T cells to control an ongoingMycobacterium tubercu-
losis infection and to limit disease lesions in lungs, where Vc9/Vd2
T cells were detected early after infection. In an alternative model
to study the effect of Vc9/Vd2 T cells in vivo, Suzanne Tomchuck
from Mari Dallas’s team (Memphis, TN) showed a beneficial roleof adoptively transferred human cord blood Vc9/Vd2 T cells
activated by zoledronate on the survival of NSG mice infected with
Streptococcus pneumoniae.
Two further studies demonstrated a protective role of murine
cd T cells against murine cytomegalovirus (MCMV) upon priming
with MCMV in vivo and transfer into immunodeficient mice, in
extension of the previously described response of human cd T cells
to CMV. In this model, Camille Khairallah from Julie Déchanet-
Merville’s laboratory (Bordeaux, France) showed the response of
spleen, liver and lung Vc1+ and Vc4+ T cells acquiring a memory
phenotype but strikingly low expression of IL-17, IFN-c and cyto-
toxic potential. Sabrina Sell from Thomas Winkler’s and Michael
Mach’s laboratories (Erlangen, Germany) demonstrated a better
control of viral spread in wild type mice when compared to TCRd-/-
mice, uncovering a non-redundant function of cd T cells against
this virus. The MCMV model might be particularly valuable to ana-
lyze the potential cooperation of cd T cells with other cells
involved in viral control such as NK cells.
In vitro investigations by different teams aimed to decipher the
mechanisms of pathogen recognition by cd T cells and their mode
of action. Christina Maher from Derek Doherty’s laboratory (Dub-
lin, Ireland) reported an IL-23 dependent expansion of IL-17-pro-
ducing Vd1+ T cells cultured in contact with Candida albicans
exposed DC. In an elegant model of latent HIV infection, Haishan
Li from David Pauza’s laboratory (Baltimore, MD) demonstrated
the killing capacity of Vc9/Vd2 T cells against CD4+ T cells reacti-
vating a latent virus, opening up perspectives for the eradication
of the latent HIV reservoir. M. tuberculosis produces HMB-PP, the
phosphoantigen with the strongest agonistic activity on Vc9/Vd2
T cells. However, by analysing the differential responses of Vc9/
Vd2 T cells to phosphoantigens and to bacillus Calmette Guérin
(BCG), Daniel Hoft (St. Louis, CO) provided evidence for the exis-
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activity, contained within methyl-glucose lipopolysaccharides
extracted from BCG.
The ultimate goal of all these studies on infectious models
should be to elaborate novel immunotherapies and vaccines based
on cd T cell activation [36]. An interesting option in that direction
was proposed by Hong Wang from Craig Morita’s laboratory (Iowa
City, IA), who engineered an attenuated strain of Salmonella enter-
ica producing high levels of HMB-PP which elicited a prolonged
expansion of Vc9/Vd2 T cells, ex vivo and in rhesus monkeys
[37]. Given their rapid expansion and immediate effector functions
during the early response to microorganisms, the evaluation of cd
T cells (and other unconventional T cells such as MAIT cells) in
infected patients might also represent reliable diagnostic or prog-
nostic biomarkers [38]. In this context, Anna Rita Liuzzi from
Matthias Eberl’s laboratory (Cardiff, UK) demonstrated the diag-
nostic value of local Vc9/Vd2 T cells as specific predictors of acute
Gram-negative infections and poor clinical outcome in peritoneal
dialysis patients [39].6. cd T cells in the tissue: immune surveillance, wound healing,
and autoimmunity
cd T cells play key roles in the regulation of inflammation
through cytokine production and cell–cell crosstalk. While inflam-
mation is necessary for the promotion of tissue repair and protec-
tion from infection, chronic inflammatory responses contribute to
a variety of conditions including non-healing wounds, cancer and
autoimmunity. Thus, cd T cells can tip the balance from a healthy
inflammatory response to a destructive disease and as such repre-
sent important therapeutic targets.
Ever since cd T cells were found to promote tissue repair in a
murine model of wound repair over a decade ago [40], there has
been controversy about whether or not a similar population exists
in human skin. Vd1+ T cells in the human epidermis were previ-
ously shown to produce IGF-1 and become activated in wounded
skin [41]. Now, Richard Woolf from Adrian Hayday’s laboratory
(London, UK) demonstrated that human Vd1+ T cells in the skin
express and are activated via the NKG2D receptor. In fact these
cells are the only T cell population in the skin with this innate-like
activation phenotype.
Murine DETC recognize an as yet unidentified antigen that
requires JAML costimulation for wound healing functions [42].
Kevin Ramirez from Wendy Havran’s laboratory (La Jolla, CA)
identified another player in the activation of this cd T cell popula-
tion. EPCR has been shown to play roles in human cd T cell
responses to CMV [23]. They now demonstrate that EPCR is upreg-
ulated on murine keratinocytes at wound sites, and that EPCR is
required for normal wound repair and epidermal cd T cell function.
To better understand signaling involved in DETC wound healing
functions, Shelley Dutt from Julie Jameson’s laboratory (San Mar-
cos, CA) investigated the role of the signaling molecule mammalian
target of rapamycin (mTOR). Murine models of wound repair in the
Jameson laboratory have shown that mTOR is required for epider-
mal cd T cell function in wound closure. They are now turning their
attention to human studies to determine whether there is a con-
centration of mTOR inhibition that impairs T cell-mediated allo-
graft rejection but allows for proper cd T cell wound healing
functions.
Tissue repair and inflammation are balanced by the potential
damage that dysregulated T cell responses can cause. Several lab-
oratories attempt to delineate the roles played by cd T cells in
modulating tissue remodeling and related disease. Shubhada Chi-
plunkar (Mumbai, India) reported that patients with gallbladder
cancer display alterations in the dynamics of Tcd17/Treg ratios.Indeed patients with an increased frequency of Tcd17 cells exhibit
poor survival, exemplifying the need to define ways to regulate the
polarization of cd T cell responses in disease. Christopher Tyler
from Matthias Eberl’s laboratory (Cardiff, UK) demonstrated that
cd T cells are able to regulate the inflammatory environment via
their ability to present antigens and promote IFN-c and IL-22 pro-
duction by CD4+ T cells, suggesting that the cellular microenviron-
ment dictates the ability of cd T cells to modulate naïve and
memory T cell responses.
Xiaoyang Wang (Göteborg, Sweden) addressed the ‘‘dark side’’
of cd T cell responses in a murine model of brain injury. While cd T
cells infiltrate the brain of wildtype mice within 6 h of hypoxia-
ischemia induction, mice lacking cd T cells exhibit reduced gray-
matter volume loss suggesting that they contribute to neonatal
brain injury. Similarly, studies by Victoria Marcu-Malina from Ilan
Bank’s laboratory (Tel Aviv, Israel) identified an immunopathogen-
ic role for cd T cells in systemic sclerosis upon zoledronate activa-
tion. In addition, a role for IL-17 producing cd T cells in ankylosing
spondylitis is being investigated by Annika Reinhardt from Immo
Prinz’s laboratory (Hannover, Germany). Entheseal CCR6+ IL-17+ cd
T cells represent a newly defined tissue-resident population with
the ability to regulate inflammatory responses. Taken together, this
session underscored the diverse functions of cd T cells and their
promising potential as therapeutic targets.7. cd T cells in cancer: immunotherapy versus tumor
progression
Almost since their discovery, cd T cells have long been known to
mediate anticancer cytotoxicity. Here, Daniel Olive (Marseille,
France) reported that human Vc9/Vd2 T cells activated by agonist
anti-BTN3A antibodies show a strong activity versus acute myeloid
leukemia cells. Gauri Mirji from Shubhada Chiplunkar’s laboratory
(Mumbai, India) showed that both human Vd1+ and Vd2+ T cells are
cytolytic for T cell acute lymphoblastic leukemia. Mohanad Nada
from Craig Morita’s laboratory (Iowa City, IA) and Ulrich Jarry from
Emmanuel Scotet’s laboratory (Nantes, France) confirmed that
human cd T cells activated by a combination of zoledronate plus
IL-15, or local administration of zoledronate plus autologous
Vc9/Vd2 T cells, represent straightforward tools for cd T cell-based
cell therapies of brain and ovarian tumors, and beyond. Hung-
Chang Chen from Matthias Eberl’s laboratory (Cardiff, UK) identi-
fied a powerful synergism between Vc9/Vd2 T cells and antigen-
specific CD8+ T cells in the eradication of human tumor cells
including breast cancer stem cells, suggesting the potential of
novel two-pronged immunotherapy strategies that combine non-
MHC restricted and MHC restricted mechanisms.
Helping cd T cells to bind and kill cancer target cells by a com-
bination of activating phosphoantigens and anticancer therapeutic
monoclonal antibodies had been investigated for non-Hodgkin
lymphoma and breast carcinoma, but the combination regimen
only starts being assessed in clinical trials [43]. In this regard, an
interesting new option was proposed by Daniela Wesch (Kiel, Ger-
many), who reported that a novel reagent called [(Her2)2  Vc9]
tribody induces an important bioactivity against pancreatic ductal
adenocarcinoma (PDAC), for which little if any treatment is avail-
able to patients [44]. A distinct yet related approach was presented
by Jonathan Fisher from John Anderson’s laboratory (London, UK),
namely that human Vd2+ T cells engineered to express a chimeric
antigen receptor targeting the ganglioside GD2 show potent effec-
tor functions against neuroblastoma and Ewing sarcoma.
In real life however, most tumors develop immune escape strat-
egies that are already in action upon diagnosis. Hence, cd T cells
have to face these successive pitfalls to successfully play their good
role. Daniel Olive (Marseille, France) illustrated this by showing
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evolved by non-Hodgkin lymphomas. Likewise, Massimo Massaia
(Torino, Italy) reported that PD-1 plays a similar role and therefore
that its blockade by targeting either PD-1+ cd cells or PD-L1+ mye-
loid-derived suppressor cells can restore human cd T cell responses
against multiple myeloma. Furthermore, Daniel Gonnermann
from Daniela Wesch’s laboratory (Kiel, Germany) showed that
prostaglandin E2, a previously described inhibitory factor for
human cd T cells [45], contributes to dampen their cytotoxicity
for PDAC.
Finally, a pejorative role for cd T cells is also part of the whole
picture, as under some yet poorly characterized circumstances
these cells could promote not only immunity but also progression
of cancer [46,47], such as human papillomavirus-driven cervix car-
cinoma, as presented by Nathalie Jacobs (Liège, Belgium). Intrigu-
ingly, Margarida Rei from Bruno Silva-Santos’s (Lisbon, Portugal)
and Daniel Pennington’s laboratories (London, UK) showed that
IL-17+ cd T cells can be deleterious in emergence of murine ovarian
cancer, possibly via secretion of pro-angiogenic and pro-inflamma-
tory factors by small peritoneal macrophages [48], in line with
Shubhada Chiplunkar’s (Mumbai, India) findings in gallbladder
cancer patients.
8. Concluding remarks
Being held 30 years after the original discovery of this enigmatic
lymphocyte subset, the 6th cd T cell conference in Chicago 2014
provided an inspiring overview of current research in the field,
with significant advances being reported as to their contribution
to immune responses in a wide range of scenarios. Particularly
noteworthy are the exciting advances and encouraging efforts to
apply this newly gained knowledge in the clinic in patients with
infections, autoimmune disorders and cancer. Although there is
still much to be learned about cd T cells and the regulatory and
effector roles they exert in the immune system, they have finally
come of age and emancipated themselves as third and independent
lymphocyte lineage whose manifold functions and unique reactiv-
ities elegantly complement and extend those of conventional ab T
cells and B cells and are critical to host defense – an evolutionary
relic no more.
The 7th cd T cell conference will be organized by Adrian
Hayday and is scheduled for 2016 in London (UK).
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